Research

23 stored records for breast cancer + BRCA2: 3 clinical trials, 3 PubMed papers, 4 Europe PMC papers, 3 St. Jude-affiliated papers, 5 NIH grants and 5 ClinVar variants. No GEO datasets are stored for this topic. TRIALS (all 3 are listed as RECRUITING): CX-5461 in solid tumours with BRCA1/2, PALB2 or homologous recombination deficiency mutations (NCT04890613, Senhwa Biosciences); SHARON, which tests chemotherapy with patients' own stem cells in metastatic cancer (NCT04150042, General Oncology); and the REPEAT trial of preoperative partial breast reirradiation and repeat breast-conserving surgery for recurrent breast cancer (NCT06640881, Amsterdam UMC). PUBMED (3, 2026): a genome-scale study identifying the FANCM-RMI1/2 complex as an opposing modulator of cell fitness after BRCA1 or BRCA2 loss (Molecular Cell, 6 Oct); the yield of actionable variants from high-risk cancer gene panel testing, in guideline-eligible and ineligible individuals (Frontiers in Genetics); and a case report of ductal carcinoma in situ arising in a fibroadenoma in a BRCA2 carrier (BMJ Case Reports, 8 Oct). EUROPE PMC (4, all 2026, none are preprints): comprehensive genomic profiling of BRCA1/2 and other susceptibility genes in breast cancer patients from Southern Tunisia; a germline BRCA2 pathogenic variant found by multigene panel testing in upper tract urothelial carcinoma; reclassification of BRCA2 variants of uncertain significance using saturation genome editing combined with clinical phenotypes; and the clinical implications of the type and genomic location of pathogenic BRCA1 and BRCA2 variants in hereditary breast and ovarian cancer. ST. JUDE-AFFILIATED PAPERS (3): a comparison of mutations in adult and adolescent/young adult colon cancer (Cancer, 2018); germline DNA-repair gene mutations, treatment exposures and subsequent neoplasms among long-term childhood cancer survivors (Journal of Clinical Oncology, 2020); and testing for adult-onset cancer predisposition syndromes in children and adolescents (Clinical Cancer Research, 2024). These concern related inherited-risk themes, not BRCA2 breast cancer specifically. CLINVAR VARIANTS (5), each with a single-submitter classification under "criteria provided": c.2637dup (p.Glu880Ter) is classified Likely pathogenic; c.197A>G (p.Gln66Arg) is Uncertain significance; c.9501+6G>C, c.9724A>G (p.Thr3242Ala) and c.9745A>G (p.Thr3249Ala) are Likely benign. These are the five the search returned, not a representative sample. NIH GRANTS (5, fiscal year 2026): PARP inhibitor resistance in IDH-mutant cancers (Yale), nucleic acid sensing in tumor cells and anti-tumor immune responses (University of Pennsylvania), managing genetic test results and outcomes after a cancer diagnosis, the Georgia-California SEER Genelink Study (Stanford), RAD51 paralog tumor suppressor complexes in genome maintenance (UT Health Science Center) and electronic-health-record support for hereditary breast and ovarian cancer genetic testing among multiethnic women (Columbia).

Written by Claude in a Claude Code session, not by the app's API summarizer. It is an AI-generated interpretation of only the records stored for this topic (titles, statuses, sponsors, journals, dates and ClinVar classifications). It is not a new source, has not been independently verified, and is not medical advice. Read the linked primary records before relying on anything here.

40 stored records for breast cancer + BRCA1: 10 clinical trials, 5 PubMed papers, 5 Europe PMC papers, 5 St. Jude-affiliated papers, 5 NIH grants, 5 ClinVar variants and 5 St. Jude-connected GEO datasets. TRIALS (all 10 are listed as RECRUITING). The largest theme is PARP-pathway treatment: a talazoparib trial in somatic BRCA-mutant metastatic breast cancer (NCT03990896, Massachusetts General Hospital), a repair-capacity test to select patients for talazoparib (NCT06193525, Erasmus MC), PARP inhibitor or capecitabine combined with PD-1 inhibitors in high-risk triple-negative breast cancer (NCT06533384, Guangdong Provincial People's Hospital) and a PARG inhibitor, ETX-19477, in advanced solid malignancies (NCT06395519, 858 Therapeutics). Others cover a personalized vaccine plus a checkpoint inhibitor in triple-negative disease (NCT06324240, Emory), circulating tumor DNA monitoring during adjuvant capecitabine (NCT04768426, Stanford), a liquid biopsy repository (NCT03702309, University Health Network, Toronto), responses to genetic risk modifier testing (NCT03396341, Memorial Sloan Kettering), intrinsic molecular subtypes in BRCA-associated breast cancer (NCT07617025) and an ovarian cancer risk prediction model for family members (NCT07039552, Peking University Third Hospital). PUBMED (5, all 2026): a PARP1-selective inhibitor, DSB1559, in triple-negative breast cancer (Journal for ImmunoTherapy of Cancer, 7 Oct); BRCA1 and BRCA2 mutation detection by next-generation sequencing in Saudi women (Clinical Laboratory); BRCA carriers and breast implant-associated anaplastic large-cell lymphoma (Annals of Surgical Oncology, 8 Oct); a case report of image-guided adaptive lattice radiotherapy for a large ulcerative triple-negative tumor (Frontiers in Oncology); and a biosensing method for breast cancer genes (Analytica Chimica Acta). EUROPE PMC (5, all 2026, none are preprints): telomere length in blood of BRCA1 mutation carriers compared with non-carriers; estrogen-receptor-positive, BRCA1-deficient breast cancer and BRCA1-epimutated tumors; pathogenic germline BRCA1/2 variants and a decreased number of hypomethylated rDNA copies; and the expanding therapeutic scope of PARP inhibitors in breast cancer. The fifth, "In This Issue: Volume 117, Issue 10, October 2026", is a journal issue listing, not a study. ST. JUDE-AFFILIATED PAPERS (5), mostly on inherited risk: ten variants associated with estrogen-receptor-negative breast cancer (Nature Genetics, 2017), 65 new breast cancer risk loci (Nature, 2017), NCCN guideline insights on high-risk assessment for breast, ovarian and pancreatic cancer (JNCCN, 2020), the genetic architecture of breast cancer risk (2023) and pathogenic BRCA1/BRCA2 variants in the Mexican population (2025). CLINVAR VARIANTS (5), each with a single-submitter classification under "criteria provided": c.387del (p.Tyr130fs) is classified Pathogenic; c.1658A>T (p.His553Leu) is Uncertain significance; c.-97C>A, c.5467+355A>C and c.*797C>A are Likely benign. These are the five the search returned, not a representative sample, and no counts of other BRCA1 variants are stored here. NIH GRANTS (5, fiscal year 2026): triple-negative breast cancer treatment combining mitochondrial gene therapy and synthetic lethal chemotherapy (Ohio State), image-guided intraductal ablation for primary breast cancer prevention (Michigan State), oncometabolites and DNA repair (Yale), PRMT5 inhibition in cancers with MTAP loss (Yale) and advanced prostate cancer in engineered mice (Columbia). The last two are not breast-specific, so this search returned some loosely related grants. DATASETS: the 5 GEO datasets (200250110, 200250111, 200250115, 200296213, 200306322) are stored as identifiers only, with no titles, so nothing can be said about their content from these records.

Written by Claude in a Claude Code session, not by the app's API summarizer. It is an AI-generated interpretation of only the records stored for this topic (titles, statuses, sponsors, journals, dates and ClinVar classifications). It is not a new source, has not been independently verified, and is not medical advice. Read the linked primary records before relying on anything here.